The Developmental Research Program is designed to support new ideas and concepts that can be incorporated into translational research projects designed to solve clinical problems in lung cancer diagnosis and therapy. The program is directed by the Developmental Research committee which makes recommendations to the Executive committee after review of each application and progress report. The Developmental Research committee is chaired by Dr. Bunn and includes members from each project and shared core resource, an advocate, a representative from NJH and two non-SPORE members. The committee receives advice from the External and Internal Advisory boards. Solicitations for new awards are sent campus wide and to all affiliated institutions. Each application is reviewed by all committee members and assigned a priority score on the basis of 1) scientific merit to impact the lung cancer burden, 2) the likelihood that the project can lead to subsequent independent funding as a full project, ROI or other fully funded project, 3) the projected interactions and collaborations between the pilot project and the SPORE, 4) the qualifications of the basic and clinical scientists involved in the pilot project, and 5) the translational potential of the proposed project. Based on the final priority scores, the Developmental Research Committee makes recommendations to the Executive Committee for final allocation of funds. Over the past 5 years there 60 applications and 14 awards totaling $700,000. Results from 4 of these projects awarded to Drs. Weiser-Evans, DeGregori, Doebele, and Heasley have been incorporated into projects proposed in this renewal and 7 of the 12 awardees are investigators in our proposed projects. Eleven of the 12 awardees continue lung cancer research. Work from 3 of the projects led to NCI R01 awards (Weiser-Evans, DeGregori, and Heasley). Other peer-reviewed follow-up lung cancer grants have been awarded to Drs. Reyland and Doebele. Work on the two most recent projects for 2012-2013 will start soon and work from last year's three awards is nearing completion. The program has been successful in replenishing new ideas to incorporate into new SPORE projects as older projects complete their goals and in developing new ideas that can be continued with other grant support.

Public Health Relevance

New research ideas are critical for studies designed to improve lung cancer diagnosis, prevention and therapy but are difficult to fund. The Developmental Research program (DRP) funds novel ideas that have the potential to transform the way we approach subjects at risk for lung cancer and with a lung cancer diagnosis. The DRP has been successful in changing the content and direction of our new SPORE projects and in obtaining external support of successful projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-23S1
Application #
9706796
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Schwartz, Elena Ivan
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
23
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770

Showing the most recent 10 out of 435 publications